• 3 September 2010

    Santhera Pharmaceuticals (SIX: SANN) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced a license agreement for the development and commercialization of fipamezole (antagonist of the adrenergic alpha-2 receptor) for territories outside of North America and Japan. This first-in-class compound is currently under investigation for the treatment of levodopa-induced dyskinesia in Parkinson's Disease. Initiation of a first Phase III study by Biovail is scheduled for 2011. Today's agreement stipulates a data sharing, under which Ipsen has the right to use these data for its own purposes.

  • 11 August 2010

    PregLem, the Swiss specialty biopharmaceutical company focused on women’s reproductive medicine, announces a world-wide, exclusive in licensing agreement for Bentamapimod, a novel, orally active, Jun Kinase Inhibitor (JNK-I AS602801) from Merck Serono for an undisclosed amount. PregLem will develop the compound for the prevention of post-surgical abdominal adhesions and endometriosis in patients with tubal ligation or comparable effective contraception.

  • 6 July 2010

    EUSA Pharma (‘EUSA’), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has granted the Japanese development and commercialization rights to its oncology therapy Erwinase® to Ohara Pharmaceutical Company Limited. The agreement represents the first product partnership EUSA has established in Japan. Under the terms of the companies’ agreement, Ohara will be responsible for any late-stage development required by the Japanese authorities, and will pay EUSA an upfront fee and royalties on future sales.

  • 18 May 2010

    PregLem, the European specialty biopharmaceutical company focused on women’s reproductive medicine, announces positive Phase III results of EsmyaTM (ulipristal acetate) for the treatment of symptomatic uterine fibroids (myoma). The PEARL II study assessed the efficacy and safety of EsmyaTM compared to the only currently approved treatment, a GnRH (gonadotropin-releasing hormone) agonist.

  • 15 March 2010

    Kuros Biosurgery AG announced today the results of a Phase IIb clinical trial assessing the potential of KUR-111 (Viz.I-0401) in the treatment of patients with tibial plateau fractures that require fixation and grafting. The study achieved its primary efficacy endpoint, which was the demonstration of statistical non-inferiority to autograft with respect to the proportion of patients who achieved radiological fracture union at 16 weeks after grafting. This is the first large scale clinical study to demonstrate the efficacy of a product based on Kuros’ proprietary bioactive-biomaterial technologies.